Physician profile
William J Dunn
NPI 1225038441
$2,166.33
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $465 · 2021: $47.28 · 2022: $182 · 2023: $1,094 · 2024: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $388.28 | 2019-2024 | Iluvien, Yutiq |
| US Retina LLC | $371.07 | 2019-2020 | |
| Genentech USA, INC. | $279.70 | 2022-2023 | Vabysmo |
| Astellas Pharma US INC | $268.03 | 2023 | Izervay |
| Regeneron Healthcare Solutions, INC. | $264.45 | 2019-2023 | Eylea, Eylea Hd |
| Coherus Oncology, INC. | $117.34 | 2022-2023 | |
| Abbvie INC. | $114.73 | 2023 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $112.85 | 2020 | |
| Novartis Pharmaceuticals Corporation | $96.70 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $89.68 | 2022-2023 | Syfovre |
| Alcon Vision LLC | $63.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,555.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.